| Barchart Demo Center |
$28.66
+0.46 (+1.63%)
as of May 31, 2024
as of May 31, 2024
| Last | 28.66 |
|---|---|
| Change | +0.46 (+1.63%) |
| Open | 28.34 |
| Prev. Close | 28.20 |
| Today's Range |
28.24
28.75
|
| 52wk Range |
25.20
40.37
|
| Volume | 78,290,000 |
| Avg Volume | 39,346,426 |
| Sector | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| PFE |
 +1.63% |
 +3.47% |
 -23.78% |
| DJIA |
+1.51% |
-2.09% |
+16.90% |
| S&P 500 |
+0.80% |
+1.01% |
+25.49% |
Key Statistics
| Annual EPS | -0.06 |
|---|---|
| Dividend Yield | 6.04% |
| P/E Ratio | 19.59 |
| Market Capitalization, $K | 157,644,609 |
| Weighted Alpha | -21.00 |
| Standard Deviation | +1.05 |
| Profit Margin | -0.56% |
| Beta | 0.63 |
Growth Rates
| YTD | -0.45% | |||
| 1-Year | -25.29% | |||
| 3-Year | -26.79% | |||
| 5-Year | -33.22% | |||
| 10-Year | -3.27% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
Pfizer’s ADCETRIS® Regimen Produces
Business Wire - 07:00AM CDT
Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS ® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients (full story)
PFE: 28.66 (+0.46)
Takeda and Pfizer Announce Four-Year Results from
Business Wire - 07:00AM CDT
Takeda ( TSE:4502/NYSE:TAK ) and Pfizer ( NYSE: PFE ) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS ® (brentuximab vedotin) in c(full story)
Pfizer’s LORBRENA® CROWN Study Shows
Business Wire - Fri May 31, 07:00AM CDT
Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA ® )(full story)
PFE: 28.66 (+0.46)
Astellas Showcases Scientific Advancements Across its
PR Newswire - Mon May 13, 07:00AM CDT
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of...(full story)
PFE: 28.66 (+0.46)
Pfizer Announces New Chief Strategy and Innovation
Business Wire - Mon May 06, 05:45AM CDT
Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team report(full story)
PFE: 28.66 (+0.46)